Abstract: Downstaging treatment by local therapy combined with systemic therapy before liver transplantation for patients with recurrent hepatocellular carcinoma (HCC) can control tumor progression and reduce tumor burden, which resulting in reducing the push-out rate of patientsduring the waiting period for liver transplantation, providing an oncological observation window,enabling patients of beyond Milan criteria downstaged with better survival benefit. The authorsintroduce the clinical experience of a case with recurrent HCC of beyond Milan criteria who underwent liver transplantation after receiving atezolizumab plus bevacizumab combined with local therapy.Results show the patient achieving pathological complete remission without postoperative rejection and obtaining a good prognosis with life status improved.